Floatz logo

Sgn-30

Hodgkin Disease

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB

View all 50 →

Same molecule, other indications

Sgn-30 is also rated in:

anaplastic large cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
nodular lymphocyte predominant Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →
Adult Lymphocyte Depletion Hodgkin LymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →